VYGR vs. PHAT, NUVB, DNA, DAWN, IMTX, ANAB, MENS, TRVI, GHRS, and URGN
Should you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Phathom Pharmaceuticals (PHAT), Nuvation Bio (NUVB), Ginkgo Bioworks (DNA), Day One Biopharmaceuticals (DAWN), Immatics (IMTX), AnaptysBio (ANAB), Jyong Biotech (MENS), Trevi Therapeutics (TRVI), GH Research (GHRS), and Urogen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry.
Voyager Therapeutics vs. Its Competitors
Phathom Pharmaceuticals (NASDAQ:PHAT) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.
In the previous week, Voyager Therapeutics had 1 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 2 mentions for Voyager Therapeutics and 1 mentions for Phathom Pharmaceuticals. Voyager Therapeutics' average media sentiment score of 0.51 beat Phathom Pharmaceuticals' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the news media.
Voyager Therapeutics has a net margin of -126.49% compared to Phathom Pharmaceuticals' net margin of -422.42%. Phathom Pharmaceuticals' return on equity of 0.00% beat Voyager Therapeutics' return on equity.
Phathom Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.
Phathom Pharmaceuticals presently has a consensus target price of $17.50, suggesting a potential upside of 94.01%. Voyager Therapeutics has a consensus target price of $13.39, suggesting a potential upside of 321.07%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Voyager Therapeutics is more favorable than Phathom Pharmaceuticals.
99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 24.1% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 4.5% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Voyager Therapeutics has higher revenue and earnings than Phathom Pharmaceuticals. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Voyager Therapeutics beats Phathom Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
Get Voyager Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Voyager Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VYGR) was last updated on 7/9/2025 by MarketBeat.com Staff
